Jun Liu
Orange,USA
Summary
Accomplished Principal Scientist with over 10 years of experience in immuno-oncology, therapeutic antibody development, and cellular immunotherapy within both academic and industry settings. Proven expertise in designing and executing in vitro and ex vivo functional assays, including ADCC, CDC, cytokine profiling, flow cytometry, and CAR-T evaluations, to support early discovery through IND-enabling studies. Strong background in molecular biology, immune cell engineering, and tumor modeling, with hands-on experience developing fully human and bispecific antibodies. Demonstrated leadership in mentoring scientific teams, managing cross-functional collaborations, and contributing to IND submissions, patents, and publications. Recognized for scientific rigor, strategic problem-solving, and driving translational research programs in fast-paced, matrixed environments.
Overview
19
19
years of professional experience
1
1
Certification
Work History
Principal Scientist
ABBRATECH
Branford, Connecticut
03.2025 - 07.2025
- Design, develop, and optimize in vitro assays to assess the biological activity, potency, and mechanism of action of therapeutic molecules.
- Conduct immunological assays including binding affinity, epitope mapping, and functional tests (ADCC, CDC, neutralization, ADC) to evaluate candidate molecules.
- Develop and support pre-clinical models, including in vivo studies, to drive IND-enabling experiments and regulatory submissions.
- Collaborate with cross-functional teams to assess pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of lead candidates.
- Partner with Contract Research Organizations and collaborators to oversee in vitro/in vivo testing and ensure comprehensive antibody characterization.
- Work closely with discovery and bioanalytical teams internally and externally to align on project timelines and objectives.
- Contribute to data analysis, interpretation, and communication in cross-functional meetings and external scientific forums.
- Support collaborations with external academic and industry partners for advanced therapeutic antibody research.
- Prepare detailed technical reports, standard operating procedures (SOPs), and regulatory documentation to support IND submissions.
- Present scientific findings at internal and external meetings, as well as contribute to publications, patents, and federal grants.
Principal Scientist
CELLINFINITY BIO
New Haven, Connecticut
07.2022 - 03.2025
- Lead CRISPR-modified CAR-T R&D, overseeing manufacturing and scale-up for tech transfer.
- Model tumor microenvironment (TME) for CAR-T ex-vivo evaluation to support CAR-T product development.
- Design and perform immune cell engineering experiments, including human primary T and NK cells, CAR construction, and functional characterization.
- Develop in vitro assays such as cell cytotoxicity assays (luciferase cytolysis assay, Incucyte assay, RTCA assay), serial coculture assays, ELISA, Luminex, and flow cytometry.
- Conduct in vivo studies including murine tumor models, adoptive cell transfer, tissue isolation, and immune readouts from CAR-T therapies.
- Regularly present findings to leadership and maintain detailed experimental records in the ELN system.
- Draft progress reports and summaries for pre-clinical IND and patent applications.
Principal Scientist
ISOPELXIS
Branford, Connecticut
02.2021 - 04.2022
- Provided scientific leadership, including advancing new assays for analysis of immune cellular reactions to various stimuli on IsoPlexis’ single-cell platform.
- Focused on immune cells, including human T cells, B cells, neutrophils, monocytes, and tumor-associated endothelial cells.
- Designed and analyzed immune cell experiments, interpreting complex data using statistical and visualization tools.
- Managed and mentored scientific staff to advance projects.
- Engaged in theoretical discussions around strategic scientific developments across projects, leading to a 20% increase in the use of single-cell secretome protocols.
- Published protocols and collaborated on strategic scientific developments across teams.
Associate Research Scientist, Neurosurgery Department
YALE UNIVERSITY
New Haven, Connecticut
12.2017 - 01.2021
- Integrated brain cancer biology and stem cell biology with translational nanotechnology for treating glioblastoma and brain diseases (stroke).
- Explored Neural Stem Cells (NSCs) mediating nanoparticle drug delivery in combination with suicide gene therapy for treating glioblastoma.
- Explored how immune cells crossed the blood-brain barrier, using a CRISPR library screen.
Postdoctoral Associate, Neurosurgery Department
YALE UNIVERSITY
New Haven, Connecticut
05.2016 - 11.2017
- Integrated brain cancer biology and stem cell biology with translational nanotechnology for treating glioblastoma and brain diseases (stroke).
Postdoctoral Associate, Genetics Department
YALE UNIVERSITY
New Haven, Connecticut
11.2011 - 04.2014
- Utilized in vitro cell culture and in vivo genetically modified mouse models to explore the microRNA mechanism of acute myeloid leukemia (AML).
- Studied micro-RNAs in promoting chemotherapy resistance in human acute myeloid leukemia (AML).
Intern
JIANGSU PROVINCE HOSPITAL
Nanjing, China
07.2006 - 06.2006
- Completed clinical rotations in Departments of Internal Medicine, Surgery, Pediatrics and Obstetrics & Gynecology.
Education
Ph.D. - Pathophysiology
NANJING MEDICAL UNIVERSITY
Nanjing, Jiangsu, China01.2011
M.D. (B.M.) - Clinical Medicine
NANJING MEDICAL UNIVERSITY
Nanjing, Jiangsu, China01.2007
Skills
- Biochemistry techniques: ELISA, Luminex, western blot, immunofluorescence, and multiplex assays
- Molecular biology: CRISPR-Cas9 editing, real-time RT-PCR, and RNA purification
- Immunology methods: CAR-T engineering, flow cytometry, and cytokine assays
- Flow cytometry expertise: LSRII, MACSQuant Analyzer 16, and FlowJo software
- Cell biology skills: Primary cell culture and lentiviral transduction
- Animal handling: Bone marrow transplantation and xenograft models
- In vivo imaging: IVIS Spectrum for tumor monitoring
- Software proficiency: Microsoft Office Suite and FACS analysis tools
- Statistical analysis: SPSS and GraphPad Prism
- Image editing: Photoshop and ImageJ
- In vitro assays
- Immunological assays
- Pre-clinical models
Languages
Fluent in Chinese.
Publications
- 1. J. Liu, X. Wang, A.T. Chen, X. Gao, B. Himes, H. Zhang, Z. Chen, J. Wang, W. Sheu, G. Deng, Y. Xiao, P. Zou, S. Zhang, F. Liu, Y. Zhu, R. Fan, T. Patel, W. Saltzman, J. Zhou. ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial linage. Nature Communications. 2022. (13) 2196.
- 2. J. Liu, B. Guo, Z. Chen, N. Wang, M. Iacovino, J. Cheng, C. Roden, W. Pan, S. Khan, S. Chen, M. Kyba, R. Fan, S. Guo, and J. Lu. MicroRNA-125b Promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell intrinsic mechanism. Blood. 2017, 129 (11): 1,491-1,502.
- 3. J. Liu, X. Luo, A. Xiong, Z. Zhang, S. Yue, M. Zhu, and S.Y. Cheng. MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. J Biol Chem. 2010, 285 (34): 26,599-26,607.
- 4. X. Li, Q. Mendez, C. Chapados, F. Acca, H. Driscoll, J. Oliveira, J. Liu, K. Jones, M. Furguson, R. Wallace, S. Bibikov, T. Lionberger, K. Harvey, M. Weiner, and G. Mirando. Site-directed antibodies targeting driver mutations of the KRAS protein. New Biotechnology. 2025, 25 (87): 112-120.
Training
- 2021-2022: Trained three employees for immune assay protocol development at IsoPlexis.
- 2012-2016: Trained two graduates and four rotation students at Yale University.
- 2009-2010: Teaching Pathophysiology (Experimental), Nanjing Medical School, Nanjing, China.
Certification
Obtained medical license in China – 2010.
Affiliations
Completed 100 hours of volunteer service assisting with patient visits at Yale New Haven Hospital.
Accomplishments
- 2009: College postgraduate innovative research award of the Jiangsu province
- 2009-2010: Awarded 1st class scholarship of Nanjing Medical Universityand “AoSaiKang” Scholarship
- 2006-2007: Awarded as the “excellent intern”
- 2005-2006: Awarded 1st class scholarship of Nanjing Medical University and the “Provincial Government Scholarship”
- 2004-2005: Awarded 1st class scholarship of Nanjing Medical University and the “merit student” of Nanjing Medical University
- 2003-2004: Awarded 1st class scholarship of Nanjing Medical University and the “outstanding student leader” of Nanjing Medical University
- 2002-2003: Awarded 3rd class scholarship of Nanjing Medical University
References
References available upon request.
Timeline
Principal Scientist
ABBRATECH
03.2025 - 07.2025
Principal Scientist
CELLINFINITY BIO
07.2022 - 03.2025
Principal Scientist
ISOPELXIS
02.2021 - 04.2022
Associate Research Scientist, Neurosurgery Department
YALE UNIVERSITY
12.2017 - 01.2021
Postdoctoral Associate, Neurosurgery Department
YALE UNIVERSITY
05.2016 - 11.2017
Postdoctoral Associate, Genetics Department
YALE UNIVERSITY
11.2011 - 04.2014
Intern
JIANGSU PROVINCE HOSPITAL
07.2006 - 06.2006
Ph.D. - Pathophysiology
NANJING MEDICAL UNIVERSITY
M.D. (B.M.) - Clinical Medicine
NANJING MEDICAL UNIVERSITY
Similar Profiles
Lourdes PallazhcoLourdes Pallazhco
Children Behavor at North Jersey TherapeuticChildren Behavor at North Jersey Therapeutic
Catherine Elizabeth MoralesCatherine Elizabeth Morales
University Treble Choir President at Chapman University College of Performing ArtsUniversity Treble Choir President at Chapman University College of Performing Arts
Terrell MartinTerrell Martin
Special Education Department Head at Bob Hope SchoolSpecial Education Department Head at Bob Hope School
JULIA FORBESJULIA FORBES
Long-Term Substitute English Teacher at Bullard-Havens Technical High SchoolLong-Term Substitute English Teacher at Bullard-Havens Technical High School
KATE HICKSKATE HICKS
Principal Scientist at Merck Sharp & Dohme, LLCPrincipal Scientist at Merck Sharp & Dohme, LLC